Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double-blind, placebo-controlled trial.
Shelby D ReedFrauke BeckerLee-Ling LimRury R HolmanAlastair M GrayPublished in: Journal of diabetes (2022)
Acarbose treatment had no impact on health-related quality of life in ACE trial participants with CHD and IGT. Events such as MI, stroke, heart failure, and angina reduce health-related quality of life around the time they occurred, but only MI and stroke impacted on longer-term health-related quality of life.
Keyphrases
- double blind
- atrial fibrillation
- heart failure
- study protocol
- phase iii
- clinical trial
- angiotensin converting enzyme
- placebo controlled
- angiotensin ii
- phase ii
- healthcare
- public health
- coronary artery disease
- mental health
- coronary artery
- preterm infants
- percutaneous coronary intervention
- randomized controlled trial
- open label
- left ventricular
- health information
- cerebral ischemia
- combination therapy
- gestational age
- acute heart failure
- brain injury
- social media
- smoking cessation
- blood brain barrier
- preterm birth